Intercept Pharmaceuticals Inc Price/Sales
What is the Price/Sales of Intercept Pharmaceuticals Inc?
The Price/Sales of Intercept Pharmaceuticals Inc is 1.45
What is the definition of Price/Sales?
Price to sales ratio is a company’s stock price compared to its revenues.
ttm (trailing twelve months)
The price to sales ratio, Price/Sales ratio, P/S ratio, or PSR, is a valuation metric for stocks. It is calculated by dividing the company's market cap by the revenue in the most recent year. It can also be calculated by dividing the per-share stock price by per-share revenue. The price to sales ratio is for trailing twelve months so the reported sales are for the four previous quarters. Longer time periods can be examined at times.
A smaller price to sales ratio is usually thought to be a better investment since the investor is paying less for each unit of sales. However, sales do not reveal the whole picture, as the company may be unprofitable with a low P/S ratio. Because of the limitations, this ratio is usually used only for unprofitable companies, since they don't have a price to earnings ratio (P/E ratio). The metric can be used to determine the value of a stock relative to its past performance. It may also be used to determine relative valuation of a sector or the market as a whole.
Price to sales ratios vary greatly between sectors, so they are most useful in comparing similar stocks within a sector or sub-sector. Comparing P/S ratios carries the implicit assumption that all firms in the comparison have an identical capital structure.
Price/Sales of companies in the Health Care sector on NASDAQ compared to Intercept Pharmaceuticals Inc
What does Intercept Pharmaceuticals Inc do?
we are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (pbc), nonalcoholic steatohepatitis (nash), primary sclerosing cholangitis (psc) and biliary atresia. in a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. we are committed to improving patients’ lives and addressing the liver community’s most pressing needs. our corporate headquarters is located in new york, and we have additional offices in san diego, london and perugia. for more information about intercept, please visit our website at: www.interceptpharma.com and follow us on twitter at: @interceptpharma.
Companies with price/sales similar to Intercept Pharmaceuticals Inc
- Quebecor has Price/Sales of 1.45
- Lucapa Diamond has Price/Sales of 1.45
- HAL Trust has Price/Sales of 1.45
- ATV Projects India has Price/Sales of 1.45
- T2 Biosystems Inc has Price/Sales of 1.45
- Liberty has Price/Sales of 1.45
- Intercept Pharmaceuticals Inc has Price/Sales of 1.45
- Glorious Sun Enterprises has Price/Sales of 1.45
- SNDL Inc has Price/Sales of 1.45
- Eurobank Ergasias SA has Price/Sales of 1.45
- O2 Micro International has Price/Sales of 1.45
- Hong Kong Television Network has Price/Sales of 1.45
- RDB Rasayans has Price/Sales of 1.45